Researchers evaluated the association of metabolic and cardiovascular comorbidities in patients with gout receiving treat-to-target uric acid lowering therapy.
Nonpharmacologic therapy may improve management and the metabolic syndrome in patients with gout.
Future research should look to improve perioperative management in people with systemic lupus erythematosus.
Disease severity and activity in psoriatic arthritis may predict coronary plaque burden better than traditional risk factors.
Improved treatment in SLE with increased life expectancy has been accompanied by an elevated risk for developing cardiovascular diseases.
Following adjustment, fracture risk was highest among patients in the lowest osteoprotegerin levels.
Psoriasis patients have high rates hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.
Researchers found that traditional cardiovascular risk factors and disease characteristics were consistently associated with vascular hemodynamic alterations in RA.
Study analyzes insurance claims data to examine the relationship between allopurinol use in patients with both gout and diabetes and its effect on cardiovascular event risk.
Researchers found a correlation between use of corticosteroids and increased odds of metabolic syndrome and elevated body mass index.
